Werewolf Therapeutics Inc（HOWL）のニュースとイベントHOWLWerewolf Therapeutics Inc

Stock Futures Rise as Investors Seek Recovery

Stock futures are higher as investors attempt to recover from Thursday's sharp selloff. Despite the rebound, all three major indexes remain on track for weekly losses, with the Dow facing its steepest weekly decline since mid-March.Long-dated Treasury yields surged this week amid concerns about rising government debt, financing needs and persistent inflation, with the 30-year yield earlier reaching its highest level since 2007. Treasury Secretary Scott Bessent said the government could further expand its Treasury repurchases after this week's intervention, but yields remain near recent highs and investors remain concerned that buybacks do not address the underlying deficit and debt outlook.Oil and geopolitics are adding to those inflation concerns. Diplomatic progress with Iran remains limited, while the U.S. is threatening tougher economic measures and Middle Eastern supply disruptions continue to support crude prices. That leaves investors weighing the prospect of renewed energy-driven inflation just as they are trying to determine the Federal Reserve's next move.Flash PMI data will provide another read on economic activity, while next week's Jackson Hole gathering, the upcoming PCE inflation report and Nvidia's earnings will be major tests for the market.In pre-market trading, S&P 500 futures fell 0.49%, Nasdaq futures fell 0.73% and Dow futures fell 0.72%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Werewolf Therapeuticsup 130% after the company and Ambros Therapeutics announced that they entered into a definitive merger agreement to combine the companies in an all-stock transactionFedExand UPSup 2% and 1% respectively after the companies were awarded Transportation Command contract modifications worth $2.72B eachBroadcomup 2% after Bloomberg reported the company is in discussions with a group of lenders to raise over $60B in debt for an AI semiconductor financing deal that will benefit Anthropic and other firmsUP AFTER EARNINGS -Ross Storesup 7%The Buckleup 4%KE Holdingsup 5%Ubiquitiup 4%BJ's Wholesaleup 2%DOWN AFTER EARNINGS -Flux Powerdown 18%OSI Systemsdown 9%Flowers Foodsdown 4%

Werewolf Therapeutics and Ambros Therapeutics Enter Merger Agreement

Werewolf Therapeutics and Ambros Therapeutics announced that they entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Ambros Therapeutics' neridronate development program in Complex Regional Pain Syndrome Type . Upon completion of the merger, the combined company will operate as Ambros Therapeutics, headquartered in San Diego, California, and is expected to trade under the Nasdaq ticker symbol (AMBX). In connection with the proposed merger, the companies secured commitments for an oversubscribed concurrent private placement of $150M from a syndicate of healthcare-dedicated investors co-led by RA Capital Management and Janus Henderson Investors. Proceeds from the proposed transaction will be used to advance the clinical development of neridronate, a differentiated bisphosphonate that has demonstrated lasting pain reduction along with improvement in other CRPS-related symptoms. Under the terms of the merger agreement, Werewolf Therapeutics will issue to pre-merger Ambros Therapeutics stockholders shares of Werewolf Therapeutics common stock as merger consideration in exchange for the cancellation of shares of capital stock of Ambros Therapeutics, and Ambros Therapeutics will become a wholly owned subsidiary of Werewolf Therapeutics. Stockholders of Ambros Therapeutics will receive newly issued shares of Werewolf Therapeutics common stock pursuant to a formula set forth in the merger agreement. The exchange ratio is based on an implied value of Ambros Therapeutics of $500M and an implied value of Werewolf Therapeutics of $47.5M. Pre-merger Werewolf Therapeutics stockholders are expected to own approximately 6.8% of the combined company, pre-merger Ambros Therapeutics stockholders are expected to own approximately 71.7% of the combined company and investors participating in the private placement are expected to own approximately 21.5% of the combined company. The percentage of the combined company that pre-merger Ambros Therapeutics stockholders and pre-merger Werewolf Therapeutics stockholders will own upon the closing of the merger is further subject to adjustment based on the amount of Werewolf Therapeutics' net cash at the time of closing. In connection with the closing of the proposed transactions, Werewolf Therapeutics stockholders will also be issued a contingent value right representing the right to receive certain payments from net proceeds received by the combined company, if any, related to dispositions of Werewolf Therapeutics' pre-transaction legacy assets. The merger agreement has been approved by the boards of directors of both companies. The transaction is expected to close by the first quarter of 2027, subject to certain closing conditions, including the approval by the stockholders of each company, the shares of Werewolf Therapeutics common stock issuable in the transaction having been approved for listing on Nasdaq, effectiveness of the registration statement on Form S-4 and the satisfaction of other customary closing conditions. Upon closing of the proposed transaction, the combined company will be led by current members of the Ambros Therapeutics leadership team.

Werewolf Therapeutics Engages Piper Sandler for Strategic Evaluation

Werewolf Therapeutics announced that the company has engaged Piper Sandler & Co. to serve as exclusive financial advisor to assist in a strategic evaluation process. "The company does not have a defined timeline for the exploration and evaluation of strategic alternatives and cannot confirm that the process will result in any strategic alternative being announced or consummated. The company cannot provide any commitment regarding when or if this strategic evaluation process will result in any type of transaction, and there can be no assurance that such activities will result in any agreements or transactions that will enhance stockholder value. The company does not intend to discuss or disclose further developments during this process unless and until its board of directors has approved a specific action or the company has otherwise determined that further disclosure is appropriate," the company said. "We have initiated a process to explore a range of alternatives available to the Company to maximize stockholder value. Such measures may include, among other options, a sale of the Company, a business combination or merger, a sale of assets, licensing or collaboration arrangements, or other strategic transactions. In addition to our clinical-stage candidates and our named earlier-stage candidates, our INDUKINE and INDUCER platforms provide exciting opportunities to apply our differentiated masking and protease linker technology in multiple additional modalities," said Daniel Hicklin, Ph.D., President and Chief Executive Officer of Werewolf.